Source: Meissner Filtration Products
Meissner Filtration Products announced today the award of a $13.4 million contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to facilitate expedited expansion of their production capacity for products critical to COVID-19 vaccine and therapeutics manufacturing.
“Meissner has experienced substantial demand for our products associated with federally funded vaccine and therapeutics manufacturing efforts,” stated Christopher Meissner, CEO of Meissner Filtration Products. “It has been incredibly fulfilling for our organization to be able to make a direct impact fighting this pandemic and this contract serves to amplify and accelerate those efforts.”